CPA3

Across TCGA pan-cancer cohorts, CPA3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPA3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CPA3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CPA3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where CPA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.895	0.269	<.001	61	view →
HNSC	DFS	Median	III,IV	1.000	0.291	.001	22	view →
PDAC	DFS	Tertile	III,IV	0.557	0.262	.006	15	view →
LUAD	DFS	Median	All	0.738	0.513	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPA3–CCRCC (DFS)

Open the CCRCC breakdown →